ICER Faces New Foe As Patient, Disability Alliance Takes Aims At Reports On Mayzent, Spravato
Executive Summary
Groups oppose use of quality-adjusted life year metric, noting ICER’s work is becoming more influential among payers. However, patient advocates do not suggest a uniform methodological alternative.
You may also be interested in...
Janssen’s Spravato Beats Antipsychotic In Depression Trial Designed To Increase Uptake
The controversial nasal spray has improved remission rates over an atypical antipsychotic in patients with a challenging form of depression, in Phase III data which could help boost its uninspiring market performance to date.
Senate Finance Panel’s New Legislative Staffer Kaltenboeck Likes QALYs For Valuing Drugs
Anna Kaltenboeck joins the committee from Memorial Sloan Kettering’s health policy group, which has been an active participant in US drug pricing reform policy development and a critic of the biopharma industry, often through public commentary by its director, Peter Bach.
ICER’s Biopharma Members: Why They Joined And What They Get
Biopharma’s funding support for the Institute for Clinical and Economic Review has been slightly above that of payers and providers for the past three to four years.